Evidence map›Paper›PMID 40277760›Full record

ReviewCurrent oncology (Toronto, Ont.)2025

Neuropilin-1: A Multifaceted Target for Cancer Therapy.

Sai Manasa Varanasi, Yash Gulani, Hari Krishnareddy Rachamala, Debabrata Mukhopadhyay, Ramcharan Singh Angom

Abstract readReview
In one paragraph

Review in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  4. Review
  5. SPP1Cell death & disease · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sai Manasa VaranasiDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0009-0003-4259-5604
Yash GulaniDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0002-8053-8702
Hari Krishnareddy RachamalaDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL 32224, USA.
Debabrata MukhopadhyayDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0003-1858-5054
Ramcharan Singh AngomDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0002-5894-1108

Funding

Targeting Pancreatic Cancer Using Peptide Chemistry: From Bench to BedsideR01CA150190 · NCI · MAYO CLINIC ROCHESTER · PI MIERKE, DALE F, MUKHOPADHYAY, DEBABRATA · 2010 to 2021
$5.7M
Regulatory Pathways and Role of VPF/VEGF in Renal CancerR01CA078383 · NCI · MAYO CLINIC ROCHESTER · PI MUKHOPADHYAY, DEBABRATA · 2004 to 2019
$4.5M
Distinct Pathways of VPF/VEGF ReceptorsR01HL140411 · NHLBI · MAYO CLINIC JACKSONVILLE · PI DEBABRATA MUKHOPADHYAY · 2018 to 2026
$4.0M
REGULATORY PATHWAYS AND ROLE OF VPF/VEGF IN RENAL CANCERR29CA078383 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MUKHOPADHYAY, DEBABRATA · 1998 to 2002
$383k
NCI NIH HHS R01 CA078383NCI NIH HHS R01 CA150190NCI NIH HHS R29 CA078383NHLBI NIH HHS R01 HL140411NIH HHS CA150190NIH HHS CA78383
6 · The paper itself

Abstract

Neuropilin-1 (NRP1), initially identified as a neuronal guidance protein, has emerged as a multifaceted regulator in cancer biology. Beyond its role in axonal guidance and angiogenesis, NRP1 is increasingly recognized for its significant impact on tumor progression and therapeutic outcomes. This review explores the diverse functions of NRP1 in cancer, encompassing its influence on tumor cell proliferation, migration, invasion, and metastasis. NRP1 interacts with several key signaling pathways, including vascular endothelial growth factor (VEGF), semaphorins, and transforming growth factor-beta (TGF-β), modulating the tumor microenvironment and promoting angiogenesis. Moreover, NRP1 expression correlates with poor prognosis in various malignancies, underscoring its potential as a prognostic biomarker. Therapeutically, targeting NRP1 holds promise as a novel strategy to inhibit tumor growth and enhance the efficacy of regular treatments such as chemotherapy and radiotherapy. Strategies involving NRP1-targeted therapies, including monoclonal antibodies, small molecule inhibitors, and gene silencing techniques, are being actively investigated in preclinical and clinical settings. Despite challenges in specificity and delivery, advances in understanding NRP1 biology offer new avenues for personalized cancer therapy. Although several types of cancer cells can express NRPs, the role of NRPs in tumor pathogenesis is largely unknown. Future investigations are needed to enhance our understanding of the effects and mechanisms of NRPs on the proliferation, apoptosis, and migration of neuronal, endothelial, and cancer cells. The novel frameworks or multi-omics approaches integrate data from multiple databases to better understand cancer's molecular and clinical features, develop personalized therapies, and help identify biomarkers. This review highlights the pivotal role of NRP1 in cancer pathogenesis and discusses its implications for developing targeted therapeutic approaches to improve patient outcomes, highlighting the role of OMICS in targeting cancer patients for personalized therapy.

Indexed as

NeoplasmsNeuropilin-1AnimalsHumansMolecular Targeted TherapyNeuropilin-1cancer stem cellscancer therapyimmunotherapyneuropilinsOMICSsemaphorinstranscriptomicstumor biologyVEGFA

Identifiers

PMID40277760
PMCPMC12025621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.